Yes. We described it as post-market surveillance in the submission. We talked about it in supporting the progressive drug licensing framework.
Executive Director, Canadian Pharmacists Association
Yes. We described it as post-market surveillance in the submission. We talked about it in supporting the progressive drug licensing framework.
See context to find out what was said next.